A chemically modified thrombolytic agent for reduced intracerebral bleeding risk

• In: Poster presentation
• At: Seoul (South Korea) (2017)
• Type: Poster
• Poster code: POS-FDP-019
• By: KWON, Young (Nova Southeastern University, Pharmaceutical Sciences, College of Pharmacy, Fort Lauderdale, United States)
• Co-author(s): Young M Kwon: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
  Wael Mahdi: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
  Gerardo Ramos: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
  
• Abstract:

  Background

  Tissue plasminogen activator (tPA) is the only FDA-approved drug for the treatment of ischemic stroke.  However, tPA is known to stimulate the production of matrix degrading enzymes, which may compromise the integrity of the blood-brain barrier (BBB), leading to intracerebral haemorrhage.  Therefore, a chemically modified thrombolytic..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login